×

Indications
ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Read more

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). ENBREL can be used with or without MTX.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older. Close

Our Lab Is Everywhere logo

Watching an airplane take flight looks easy and smooth. It's actually a meticulous science based on accurate and consistent measurements. Combustors precisely regulate the fuel injection rate to help maintain a controlled and consistent propulsion during flight. Similarly, the self-injection process aims to bring a consistent and controlled experience. Our device engineers explored the operational components.

See what we discovered

Our lab

Striving for Consistency with the Self-Injection


Striving for consistency with the self-injection

Planes taking flight are designed to create a repeatable and reliable experience. With self-injection now a common practice for patients with diseases ranging from rheumatoid arthritis to diabetes, shouldn't these patients be able to rely on a consistent injection experience?

We looked at some common self-injection devices for insight into how they are designed for consistency and control.

Prefilled syringe administration

A Controlled Dose

Prefilled syringes

Unlike products that may require premixing or drawing the medication from a vial, the prefilled syringe comes ready with a consistent drug volume. This manual option gives patients control over the speed of needle insertion as well as medication extrusion.

As a healthcare professional, you may remember being trained to puncture the skin quickly using a dart-like motion to insert the needle for subcutaneous injections. Patients are oftentimes instructed to do the same while self-injecting.

Whether patients prefer it fast or slow, they have the control while self-administering.

Control while self-administering
Spring-loaded pen injector administration

Click of a Button

Spring-loaded pen injectors

Some spring-loaded pen injectors come prefilled and include a hidden needle. This can help to shorten preparation time of the medication prior to the injection.

Automated for consistency with the push of a button, many pen injectors use tension from a single spring to trigger both needle insertion and medication extrusion.

With this automated device, injection rate is determined by the spring’s tension rather than a user-controlled depression of the plunger.

Rate determined by spring’s tension
Electromechanical automation

Electromechanical Automation

This website is for informational purposes intended for healthcare professionals only. If you are not a healthcare professional, please contact your doctor about ENBREL. Patients should be trained by a healthcare professional prior to using the Enbrel Mini® cartridge with AutoTouch® autoinjector. Detailed instructions are provided in the Instructions for Use.

In November 2017, we introduced a different injection device. Our device engineers utilized electromechanical technology to create a final product that would ensure a consistent delivery time.

In order to create the level of automated control needed, the device was designed to house 2 distinct motors–one for each unique force needed while injecting.

The first motor ensures fast needle penetration and is similar to the fast darting motion used with a syringe, with a minimum needle insertion speed of 200 millimeters per second (mm/s).

The second motor allows patients to control plunger extrusion force to their comfort preference, with minimum drug delivery speeds of 6 mm/s, 5 mm/s, or 4 mm/s.

No matter which speed patients choose, they get a consistent delivery of ENBREL with 3 preset speeds.

Two distinct motors for needle insertion and medication extrusion

Enbrel Mini® cartridge with AutoTouch® autoinjector Innovative features designed with patient insights

In a usability study of 60 participants who practiced a simulated injection*
0% agreed or strongly agreed that they always felt in control of their injection from start to finish with Enbrel Mini® with AutoTouch®

*Enbrel Mini® with AutoTouch® Usability Study Design In a multicenter usability study, 60 participants—55 adult patients taking medication for RA, PsO, PsA, or AS, plus 5 caregivers—were asked to rate their agreement from 1 (strongly disagree) to 5 (strongly agree) with the statement "I always felt in control of my injection, from start to finish". Each interview introduced the product, provided IFU-based training, and provided time to review the device and labeling. Participants practiced a simulated injection with a prototype device and cartridge that did not contain needle or fluid. †RA—Rheumatoid Arthritis; PsO—Plaque Psoriasis; PsA—Psoriatic Arthritis; AS—Ankylosing Spondylitis; IFU—Instructions for Use.

See more patient feedback

ENBREL® (etanercept) logo

We are ENBREL—our drive is enduring and our lab is everywhere

Our drive to find patient-centric solutions is enduring

Our lab
Prescription Enbrel® (etanercept) is administered by injection.

Important Safety Information and Indications

SERIOUS INFECTIONS

Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.

Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric Patients

In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

NEUROLOGIC REACTIONS

Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

CONGESTIVE HEART FAILURE

Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC REACTIONS

Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.

HEPATITIS B REACTIVATION

Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients.

ALLERGIC REACTIONS

Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.

IMMUNIZATIONS

Live vaccines should not be administered to patients on ENBREL. Pediatric patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, temporarily discontinue ENBREL and consider prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITY

Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.

WEGENER’S GRANULOMATOSIS PATIENTS

The use of ENBREL in patients with Wegener’s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.

MODERATE TO SEVERE ALCOHOLIC HEPATITIS

Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONS

The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.

In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.

DRUG INTERACTIONS

The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Please see Prescribing Information and Medication Guide.



INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). ENBREL can be used with or without MTX.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

See More Close